Table 3.
Surgicopathological characteristics (n = 94).
| Characteristics | Presurgical EB/imaging | Final HPR | Correctly reported presurgical | Percentage |
|---|---|---|---|---|
| Histology | ||||
| Endometrioid adenocarcinoma | 82 | 76 | 68/76 | |
| Adenosquamous carcinoma | 04 | 03 | 02/03 | |
| Papillary serous carcinoma | 04 | 08 | 03/08 | |
| Clear cell carcinoma | 04 | 03 | 03/03 | |
| Endometrial hyperplasia | 00 | 02 | 0/02 | |
| Proliferative endometrium | 00 | 02 | 0/02 | |
| (no malignancy/hyperplasia) | ||||
| Total | 76/94 | 80.85% | ||
| Tumor grade | ||||
| High grade | 24 | 32 | 18/32 | 56.25% |
| Grade1/2 endometrioid | 70 | 62 | 56/62 | 90.32% |
| Total | 74/94 | 78.72% | ||
| Cervical extension (stroma) | 04 | 06 | 4/6 | 66.66% |
| Tumor diameter on MRI | ||||
| <2 cm | 38 | 46 | 36/46 | 78.2% |
| >2 cm | 56 | 48 | 44/48 | 91.66% |
| Myometrial invasion | ||||
| <50% | 42 | 38 | 34/42 | 80.90 |
| >50% | 52 | 56 | 48/56 | 85.71 |
| Nodal metastasis (MRI+PET) | 18 | 22 | 12/22 | 55.54 |
| Pelvic only | 20 | 16 | – | |
| Para-aortic only | 2 | 2 | – | |
| Pelvic and para-aortic | 6 | 4 | – | |
| Abdominal disease | 02 | 03 | 2/3 | 66.66 |
| Gross | 02 | 02 | 2/2 | 100 |
| Microscopic | 00 | 01 | 0/1 | 0 |
| Cytology positive | – | 05 | – | – |
| Staging | ||||
| Stage 1A | 24 | 32 | – | |
| Stage 1B | 34 | 29 | – | |
| Stage II | 4 | 4 | – | |
| Stage IIIA | 2 | 5 | – | |
| Stage IIIB | 2 | 3 | – | |
| Stage IIIC1 | 20 | 16 | – | |
| Stage IIIC2 | 6 | 4 | – | |
| Stage IV | 2 | 1 | – | |
EB, endometrial biopsy; HPR, final histopathology report; MRI, magnetic resonance imaging; PET: Positron emission tomography.